Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
12.57
+0.72 (6.08%)
Mar 4, 2026, 4:00 PM EST - Market closed
Entrada Therapeutics Employees
Entrada Therapeutics had 152 employees as of December 31, 2025. The number of employees decreased by 31 or -16.94% compared to the previous year.
Employees
152
Change (1Y)
-31
Growth (1Y)
-16.94%
Revenue / Employee
$167,243
Profits / Employee
-$945,724
Market Cap
452.52M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 152 | -31 | -16.94% |
| Dec 31, 2024 | 183 | 24 | 15.09% |
| Sep 30, 2024 | 177 | 27 | 18.00% |
| Jun 30, 2024 | 168 | 37 | 28.24% |
| Mar 31, 2024 | 160 | 30 | 23.08% |
| Dec 31, 2023 | 159 | 29 | 22.31% |
| Sep 30, 2023 | 150 | 26 | 20.97% |
| Jun 30, 2023 | 131 | 9 | 7.38% |
| Mar 31, 2023 | 130 | 16 | 14.04% |
| Dec 31, 2022 | 130 | 16 | 14.04% |
| Sep 30, 2022 | 124 | 26 | 26.53% |
| Jun 30, 2022 | 122 | 44 | 56.41% |
| Mar 31, 2022 | 114 | 36 | 46.15% |
| Dec 31, 2021 | 114 | - | - |
| Sep 30, 2021 | 98 | - | - |
| Jun 30, 2021 | 78 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 834 |
| Absci | 157 |
| Century Therapeutics | 150 |
| Enanta Pharmaceuticals | 120 |
| Keros Therapeutics | 82 |
| Armata Pharmaceuticals | 60 |
| Tectonic Therapeutic | 60 |
| Anavex Life Sciences | 34 |
TRDA News
- 1 day ago - Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 15 days ago - Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study - GlobeNewsWire
- 4 weeks ago - Entrada Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Entrada Therapeutics, Inc. (TRDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - GlobeNewsWire
- 2 months ago - Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts - Seeking Alpha